Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 4:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 257 matching trials from the live ClinicalTrials.gov search.
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
CAL101, Placebo
Drug
Lead sponsor
Calluna Pharma AS
Industry
Eligibility
40 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Denver, Colorado • Miami, Florida + 6 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Idiopathic Pulmonary Fibrosis, Lung Disease, Pulmonary Fibrosis
Interventions
Interferon gamma-1b ("Actimmune")
Drug
Lead sponsor
InterMune
Industry
Eligibility
40 Years to 79 Years
Enrollment
826 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Brisbane, California
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DWN12088, Placebo
Drug
Lead sponsor
Daewoong Pharmaceutical Co. LTD.
Industry
Eligibility
40 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
20
States / cities
Mesa, Arizona • Phoenix, Arizona • San Francisco, California + 14 more
Completed No phase listed Observational Results available

Dose Reduction and Discontinuation With Anti-Fibrotic Medications

NCT05779007
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Pirfenidone, Nintedanib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,778 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Ridgefield, Connecticut
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Ambrisentan, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
40 Years to 80 Years
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 48 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Nintedanib, Pirfenidone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 80 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
16
States / cities
Los Angeles, California • Stanford, California • Sarasota, Florida + 12 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
QAX576
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Denver, Colorado • Atlanta, Georgia • New Orleans, Louisiana + 3 more
Completed Not applicable Interventional Results available

Treatment of IPF With Laparoscopic Anti-Reflux Surgery

NCT01982968
Conditions
Idiopathic Pulmonary Fibrosis, Gastroesophageal Reflux
Interventions
Surgery
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
San Francisco, California • Chicago, Illinois • Ann Arbor, Michigan + 2 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
GC1008
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 79 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
7
States / cities
Denver, Colorado • Chicago, Illinois • Ann Arbor, Michigan + 4 more
Conditions
Pulmonary Fibrosis, Pulmonary Hypertension
Interventions
Iloprost Inhalation Solution (Ventavis)
Drug
Lead sponsor
Actelion
Industry
Eligibility
40 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more
Conditions
Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
Interventions
Treprostinil sodium for inhalation
Drug
Lead sponsor
Lung Biotechnology PBC
Industry
Eligibility
35 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
La Jolla, California • Sacramento, California • Ann Arbor, Michigan + 3 more
Active, not recruiting Early Phase 1 Interventional

FAPI PET for Lung Fibrosis

NCT05365802
Conditions
Interstitial Lung Disease, Idiopathic Interstitial Pneumonias, Drug-Induced Pneumonitis, Hypersensitivity Pneumonitis, Radiation Pneumonitis, Pneumoconiosis, Pulmonary Fibrosis
Interventions
68Ga-FAPi-46, Computed Tomography, Positron Emission Tomography, High Resolution Computed Tomography
Drug · Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Recruiting No phase listed Observational Accepts healthy volunteers

A Study of the Natural Progression of Interstitial Lung Disease (ILD)

NCT00470327
Conditions
Interstitial Lung Diseases, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Connective Tissue Disorder
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
PRM-151 (Zinpentraxin Alfa), Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 85 Years
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 64 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Gefapixant
Drug
Lead sponsor
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
40 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Charlotte, North Carolina
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
warfarin, placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
35 Years to 80 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 19 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Garadacimab, Placebo
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
40 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Huntington Beach, California + 19 more
Conditions
Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement
Interventions
Vixarelimab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 21 more
Conditions
Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis
Interventions
Pirfenidone
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
27
States / cities
Phoenix, Arizona • Pomona, California • San Jose, California + 22 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Tetrathiomolybdate
Drug
Lead sponsor
University of Michigan
Other
Eligibility
35 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Pulmonary Fibrosis, Lung Cancer
Interventions
[68Ga]CBP8, PET Imaging
Drug · Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Active, not recruiting Phase 2 Interventional

Xenon MRI and Progressive ILD

NCT05241275
Conditions
Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Interventions
Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Standard pulmonary rehabilitation program
Other
Lead sponsor
National Jewish Health
Other
Eligibility
40 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Denver, Colorado